CAESAREA, Israel--(BUSINESS WIRE)--Itamar Medical, the world's leading developer of non-invasive technology for early detection of cardiovascular disease and home testing of obstructive sleep apnea, continues to penetrate new markets and has announced a breakthrough in South America by receiving ANVISA certification. The flagship products, WatchPAT and EndoPAT, may now be imported and sold freely to the clinical market of South America.
In addition, Itamar Medical announced the signing of an exclusive distribution agreement with Politec Saúde, one of the largest companies in Brazil, as well as with Smart Medical for the distribution of the WatchPAT in Chile.
“Politec Saúde, as the exclusive distributor of Itamar products in Brazil, is proud to help Brazilian HealthCare professionals and patients with this great new technology,” said Claudio Rigamonti, President of Politec Saúde.
Brazil, the largest economy in the CALA (Central America / Latin America) region, is experiencing a good growth rate in recent years. Both Itamar products are being used for research purposes in leading university hospitals in all major Brazilian cities. The EndoPAT is currently part of the ELSA study that is covering 6 Brazilian states and has the objective to set the benchmark for investigating mainly cardiovascular disease, diabetes, biological, behavioral, environmental, occupational and social behavior.
“Brazil, which boasts a population of 190 million people, offers great potential for WatchPAT home testing to surpass in-lab sleep labs and greater cost savings for consumers,” said Dr. Dov Rubin, CEO and President Itamar Medical. “We expect to see similar success for EndoPAT.”
About Itamar Medical
Itamar Medical Ltd. is a publicly-traded medical technology company (TASE: ITMR) utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to both the cardiovascular and autonomic nervous systems. For more information, visit www.itamar-medical.com.